Epizyme to Participate in Wedbush 2012 Life Sciences: Management Access Conference

Epizyme to Participate in Wedbush 2012 Life Sciences: Management Access Conference

<0> MacDougall Biomedical CommunicationsKari Watson or Jennifer Conrad, 781-235-3060 </0>

, a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, today announced its participation in the at Le Parker Meridien in New York City, NY, presenting on Wednesday, August 15 at 3:40 PM.

Epizyme is leading the creation of small molecule histone methyltransferase inhibitors (HMTi), a new class of personalized therapeutics for patients with genetically defined cancers. Genetic alterations in HMTs, a family of epigenetic enzymes, drive multiple human diseases. Our approach represents the future of healthcare by matching better medicines with the right patients.

Epizyme has benchmark partnerships with Celgene, GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS).

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.